UNSPSC 51191506: Amiloride

This classification denotes a potassium-sparing diuretic and intercalating agent with the molecular formula C6H8ClN7O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7DZO8EB0Z3, chemically known as 3,5-diamino-n-(aminoiminomethyl)-6-chloropyrazinecarboxamide but generally known as amiloride, which bears US NIH Compound Identifier 16231. Amiloride most often comes in caproate, chloride, hydrochloride, hydrochloride dihydrate, and hydrochloride-hydrochlorothiazide forms.

UNSPSC 51191506 Amiloride is a Commodity code nominally covering a specific diuretic pharmaceutical product, but recent state and local solicitations tagged under this code show minimal alignment with the code's stated scope. The City of Meriden's recent bid (B027-15, due July 29, 2026) solicits sodium bisulfite, a water-treatment chemical used in municipal pollution control, which falls outside pharmaceutical procurement entirely. A second opportunity from the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across state and local government facilities in Minnesota and Oregon—a broad pharmaceutical-supply agreement that does not specifically reference amiloride or target a single active ingredient. The mismatch between the code's nominal scope and the actual commodities being solicited indicates that this code shows little relevant recent activity aligned with amiloride procurement.

The two opportunities reflect disparate buying patterns: Meriden's chemical-supply IFB targets a single municipal water utility with standard bonding and insurance requirements, while MMCAP's multi-state RFP coordinates purchasing across participating state and local health and welfare facilities through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson), with awards effective July 1, 2026 and two-year contract terms. No recent solicitations directly target amiloride as a line item or specify this drug by National Drug Code (NDC). Firms evaluating this code should verify whether the tagging reflects procurement system miscategorization or whether state and local buyers are grouping amiloride with broader diuretic or cardiovascular drug classes in cooperative purchasing vehicles. The absence of amiloride-specific opportunities suggests either low volume or systematic misclassification in the UNSPSC taxonomy at the state and local level.